Cue Biopharma Appoints Shao-Lee Lin as CEO, President, and Director
Cue Biopharma has officially appointed Shao-Lee Lin as its new Chief Executive Officer, President, and member of the Board of Directors. Lin succeeds Lucinda Warren, who served as the Interim President and CEO. With over 25 years of experience in the biopharmaceutical industry, Lin brings a robust leadership background, having previously founded and led Acelyrin. Her career includes significant roles at major industry players such as Horizon Therapeutics, AbbVie, Gilead Sciences, and Amgen, where she specialized in advancing therapies from concept to clinical stages. Pasha Sarraf, Chairman of Cue Biopharma’s board, praised Lin’s disciplined approach to company growth and her track record in developing breakthrough treatments. In her inaugural statement, Lin highlighted the company’s strategic focus on CUE-401, a candidate for autoimmune diseases currently moving toward Phase 1 trials. She also announced an upcoming Phase 2 program targeting allergic diseases, projecting a potential functional cure and significant corporate growth by the second half of 2026. Cue Biopharma remains dedicated to developing therapeutic biologics that modulate disease-specific T cells for treating autoimmune and inflammatory conditions.
Wire timeline
Cue Biopharma Appoints Shao-Lee Lin as CEO, President, and Director
Cue Biopharma has officially appointed Shao-Lee Lin as its new Chief Executive Officer, President, and member of the Board of Directors. Lin succeeds Lucinda Warren, who served as the Interim President and CEO. With over 25 years of experience in the biopharmaceutical industry, Lin brings a robust leadership background, having previously founded and led Acelyrin. Her career includes significant roles at major industry players such as Horizon Therapeutics, AbbVie, Gilead Sciences, and Amgen, where she specialized in advancing therapies from concept to clinical stages. Pasha Sarraf, Chairman of Cue Biopharma’s board, praised Lin’s disciplined approach to company growth and her track record in developing breakthrough treatments. In her inaugural statement, Lin highlighted the company’s strategic focus on CUE-401, a candidate for autoimmune diseases currently moving toward Phase 1 trials. She also announced an upcoming Phase 2 program targeting allergic diseases, projecting a potential functional cure and significant corporate growth by the second half of 2026. Cue Biopharma remains dedicated to developing therapeutic biologics that modulate disease-specific T cells for treating autoimmune and inflammatory conditions.
PMLiVE